The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Articles / Jun / Optimizing AAV Manufacture-old
Manufacture Cell & Gene Bioprocessing Biopharma Sponsored

Optimizing AAV Manufacture-old

06/22/2020 1 min read

Sponsored By

Share

With the potential to cure genetic disorders rather than just alleviate symptoms, gene therapies look set to revolutionize the field of medicine. Adeno-associated viruses have emerged as the vector of choice for delivering therapeutic genes to target cells, but manufacturing processes need to be improved and optimized to unlock their full potential.

In this feature, we discuss the significant progress made in our ability to deliver therapeutic genes to target cells – and the many challenges on the road ahead.

Complete this form to access the article.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

Musings from The Power List: Ali Pashazadeh
Outsourcing Biopharma Business & Trends
Musings from The Power List: Ali Pashazadeh

August 7, 2026

7 min read

Ali Pashazadeh argues that management failures sink too many clinical programs – and explains why commercial discipline must start much earlier

Moving Glycosylation Control Upstream
Biopharma Interviews Technology & Manufacturing
Moving Glycosylation Control Upstream

August 6, 2026

7 min read

Samsung Biologics’ Sojeong Lee discusses why biologics developers are paying closer attention to glycosylation earlier in development.

How China Is Rewriting the Rules Global Drug Development
Development & Clinical Biopharma Interviews
How China Is Rewriting the Rules Global Drug Development

August 5, 2026

14 min read

In part two of our conversation, Lingshi Tan explores how China’s integrated biopharma ecosystem is reshaping assumptions about speed, cost, innovation, and cross-border clinical development

The 10 Biggest Bottlenecks Slowing Drug Development
Development & Clinical Business & Trends Biopharma
The 10 Biggest Bottlenecks Slowing Drug Development

August 4, 2026

6 min read

Ten industry leaders from the 2026 Power List identify the scientific, clinical, regulatory, and financial barriers holding drug development back

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: